List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3528802/publications.pdf Version: 2024-02-01

		1531	2453
502	49,611	109	203
papers	citations	h-index	g-index
512	512	512	46959
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents. Journal of Nanobiotechnology, 2022, 20, 64.	4.2	5
2	Dictating Phenotype, Function, and Fate of Human T Cells with Co‣timulatory Antibodies Presented by Filamentous Immune Cell Mimics. Advanced Therapeutics, 2022, 5, .	1.6	8
3	Immunological responses to adjuvant vaccination with combined CD1c <sup>+</sup> myeloid and plasmacytoid dendritic cells in stage III melanoma patients. OncoImmunology, 2022, 11, .	2.1	14
4	Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion. , 2022, 10, e004309.		8
5	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
6	Dual Site-Specific Chemoenzymatic Antibody Fragment Conjugation Using CRISPR-Based Hybridoma Engineering. Bioconjugate Chemistry, 2021, 32, 301-310.	1.8	19
7	PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses. Frontiers in Immunology, 2021, 12, 641703.	2.2	21
8	Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3â€dioxygenase 1 with functional effects on T cell priming. European Journal of Immunology, 2021, 51, 1494-1504.	1.6	11
9	Semiflexible Immunobrushes Induce Enhanced T Cell Activation and Expansion. ACS Applied Materials & Interfaces, 2021, 13, 16007-16018.	4.0	14
10	Enhanced Antitumor Efficacy through an "AND gate―Reactive Oxygenâ€5peciesâ€Dependent pHâ€Respon Nanomedicine Approach. Advanced Healthcare Materials, 2021, 10, e2100304.	sive 3.9	9
11	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
12	Three distinct tolerogenic CD14+ myeloid cell types to actively manage autoimmune disease: Opportunities and challenges. Journal of Autoimmunity, 2021, 120, 102645.	3.0	4
13	Characterization of Intrinsically Radiolabeled Poly(lactic- <i>co</i> -glycolic acid) Nanoparticles for ex Vivo Autologous Cell Labeling and in Vivo Tracking. Bioconjugate Chemistry, 2021, 32, 1802-1811.	1.8	7
14	Metabolic Screening of Cytotoxic T-cell Effector Function Reveals the Role of CRAC Channels in Regulating Lethal Hit Delivery. Cancer Immunology Research, 2021, 9, 926-938.	1.6	5
15	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. Blood, 2021, 138, 1570-1582.	0.6	9
16	Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. Nature Communications, 2021, 12, 5217.	5.8	99
17	In Vivo PET Imaging of Monocytes Labeled with [89Zr]Zr-PLGA-NH2 Nanoparticles in Tumor and Staphylococcus aureus Infection Models. Cancers, 2021, 13, 5069.	1.7	4
18	Robust Antigen-Specific T Cell Activation within Injectable 3D Synthetic Nanovaccine Depots. ACS Biomaterials Science and Engineering, 2021, 7, 5622-5632.	2.6	4

#	Article	lF	CITATIONS
19	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. BMJ Open, 2021, 11, e050725.	0.8	21
20	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 536700.	1.3	4
21	The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. Nature Communications, 2020, 11, 2749.	5.8	51
22	Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses. Oncolmmunology, 2020, 9, 1738813.	2.1	37
23	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunology, Immunotherapy, 2020, 69, 477-488.	2.0	42
24	Collective invasion induced by an autocrine purinergic loop through connexin-43 hemichannels. Journal of Cell Biology, 2020, 219, .	2.3	21
25	Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics, 2019, 9, 7924-7947.	4.6	77
26	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. , 2019, 7, 302.		72
27	Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering. Science Advances, 2019, 5, eaaw1822.	4.7	13
28	Synthetic Semiflexible and Bioactive Brushes. Biomacromolecules, 2019, 20, 2587-2597.	2.6	10
29	ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation. Molecules, 2019, 24, 1825.	1.7	10
30	Multicore Liquid Perfluorocarbonâ€Loaded Multimodal Nanoparticles for Stable Ultrasound and <sup>19</sup> F MRI Applied to In Vivo Cell Tracking. Advanced Functional Materials, 2019, 29, 1806485.	7.8	47
31	Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity. Frontiers in Immunology, 2019, 10, 824.	2.2	29
32	Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells. Frontiers in Immunology, 2019, 10, 931.	2.2	15
33	Förster Resonance Energy Transfer-Based Stability Assessment of PLGA Nanoparticles in Vitro and in Vivo. ACS Applied Bio Materials, 2019, 2, 1131-1140.	2.3	21
34	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. Clinical and Translational Oncology, 2019, 21, 774-780.	1.2	7
35	Microfluidics-Assisted Size Tuning and Biological Evaluation of PLGA Particles. Pharmaceutics, 2019, 11, 590.	2.0	26
36	Intracellular Galectin-9 Controls Dendritic Cell Function by Maintaining Plasma Membrane Rigidity. IScience, 2019, 22, 240-255.	1.9	23

#	Article	IF	CITATIONS
37	Cross-talk between iNKT cells and CD8 T cells in the spleen requires the IL-4/CCL17 axis for the generation of short-lived effector cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25816-25827.	3.3	22
38	Endolysosomalâ€Escape Nanovaccines through Adjuvantâ€Induced Tumor Antigen Assembly for Enhanced Effector CD8 <sup>+</sup> T Cell Activation. Small, 2018, 14, e1703539.	5.2	38
39	Design of triphasic poly(lactic- <i>co</i> -glycolic acid) nanoparticles containing a perfluorocarbon phase for biomedical applications. RSC Advances, 2018, 8, 6460-6470.	1.7	14
40	Synthetic immune niches for cancer immunotherapy. Nature Reviews Immunology, 2018, 18, 212-219.	10.6	141
41	Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. Journal of Immunology, 2018, 200, 347-354.	0.4	181
42	Injectable Biomimetic Hydrogels as Tools for Efficient T Cell Expansion and Delivery. Frontiers in Immunology, 2018, 9, 2798.	2.2	60
43	Biophysical Characterization of CD6—TCR/CD3 Interplay in T Cells. Frontiers in Immunology, 2018, 9, 2333.	2.2	12
44	C-type lectin-like receptor 2 (CLEC-2)-dependent DC migration is controlled by tetraspanin CD37. Journal of Cell Science, 2018, 131, .	1.2	12
45	Dendritic cells in cancer immunotherapy. Nature Materials, 2018, 17, 474-475.	13.3	92
46	A comparative assessment of continuous production techniques to generate sub-micron size PLGA particles. International Journal of Pharmaceutics, 2018, 550, 140-148.	2.6	29
47	Cytokineâ€Functionalized Synthetic Dendritic Cells for TÂCell Targeted Immunotherapies. Advanced Therapeutics, 2018, 1, 1800021.	1.6	25
48	Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells. Nature Communications, 2018, 9, 3317.	5.8	116
49	Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity. Nanomedicine, 2017, 12, 491-510.	1.7	44
50	Controlling T-Cell Activation with Synthetic Dendritic Cells Using the Multivalency Effect. ACS Omega, 2017, 2, 937-945.	1.6	48
51	Affinity-Based Purification of Polyisocyanopeptide Bioconjugates. Bioconjugate Chemistry, 2017, 28, 2560-2568.	1.8	11
52	N-glycan mediated adhesion strengthening during pathogen-receptor binding revealed by cell-cell force spectroscopy. Scientific Reports, 2017, 7, 6713.	1.6	19
53	Migrating into the Tumor: a Roadmap for T Cells. Trends in Cancer, 2017, 3, 797-808.	3.8	230
54	A membrane-anchored aptamer sensor for probing IFNÎ <sup>3</sup> secretion by single cells. Chemical Communications, 2017, 53, 8066-8069.	2.2	58

#	Article	IF	CITATIONS
55	Multispectral imaging for highly accurate analysis of tumourâ€infiltrating lymphocytes in primary melanoma. Histopathology, 2017, 70, 643-649.	1.6	14
56	Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy. Oncotarget, 2017, 8, 19879-19893.	0.8	20
57	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. Oncotarget, 2017, 8, 54434-54443.	0.8	13
58	Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. Oncotarget, 2017, 8, 67439-67456.	0.8	15
59	A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets. Mediators of Inflammation, 2016, 2016, 1-11.	1.4	57
60	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. Journal of Immunotherapy, 2016, 39, 241-248.	1.2	26
61	Dendritic Cell–Based Immunotherapy: State of the Art and Beyond. Clinical Cancer Research, 2016, 22, 1897-1906.	3.2	295
62	Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunology, Immunotherapy, 2016, 65, 1249-1259.	2.0	67
63	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. Cancer Research, 2016, 76, 3496-3506.	0.4	33
64	Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. Ophthalmology, 2016, 123, 2265-2267.	2.5	44
65	Human CD1c <sup>+</sup> DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncolmmunology, 2016, 5, e1192739.	2.1	74
66	Lipid peroxidation causes endosomal antigen release for cross-presentation. Scientific Reports, 2016, 6, 22064.	1.6	120
67	Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function. Cell Reports, 2016, 16, 2953-2966.	2.9	72
68	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. Journal of Translational Medicine, 2016, 14, 88.	1.8	10
69	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncolmmunology, 2016, 5, e1191732.	2.1	17
70	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. Oncolmmunology, 2016, 5, e1201625.	2.1	21
71	Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. Cancer Research, 2016, 76, 4332-4346.	0.4	93
72	Cancer vaccine triggers antiviral-type defences. Nature, 2016, 534, 329-331.	13.7	27

#	Article	IF	CITATIONS
73	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncolmmunology, 2016, 5, e1057673.	2.1	67
74	Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunology, Immunotherapy, 2016, 65, 327-339.	2.0	50
75	Long-lasting multifunctional CD8 <sup>+</sup> T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. Oncolmmunology, 2016, 5, e1067745.	2.1	55
76	Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses. OncoImmunology, 2016, 5, e1068493.	2.1	68
77	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clinical Cancer Research, 2016, 22, 2155-2166.	3.2	211
78	Semaphorin 7A Promotes Chemokine-Driven Dendritic Cell Migration. Journal of Immunology, 2016, 196, 459-468.	0.4	35
79	Tetraspanin CD37 protects against the development of B cell lymphoma. Journal of Clinical Investigation, 2016, 126, 653-666.	3.9	47
80	Proteome Based Construction of the Lymphocyte Function-Associated Antigen 1 (LFA-1) Interactome in Human Dendritic Cells. PLoS ONE, 2016, 11, e0149637.	1.1	2
81	The tetraspanin web revisited by super-resolution microscopy. Scientific Reports, 2015, 5, 12201.	1.6	123
82	Type I IFNâ€mediated synergistic activation of mouse and human DC subsets by TLR agonists. European Journal of Immunology, 2015, 45, 2798-2809.	1.6	17
83	AFM force spectroscopy reveals how subtle structural differences affect the interaction strength between <i>Candida albicans</i> and DC-SIGN. Journal of Molecular Recognition, 2015, 28, 687-698.	1.1	15
84	Multispectral imaging reveals the tissue distribution of tetraspanins in human lymphoid organs. Histochemistry and Cell Biology, 2015, 144, 133-146.	0.8	23
85	Targeted Delivery of a Sialic Acid-Blocking Glycomimetic to Cancer Cells Inhibits Metastatic Spread. ACS Nano, 2015, 9, 733-745.	7.3	123
86	Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunology, Immunotherapy, 2015, 64, 831-842.	2.0	27
87	Immune infiltrates impact on the prediction of prognosis and response to immunotherapy of melanoma patients. Journal of Translational Medicine, 2015, 13, P12.	1.8	2
88	Design of a Highly Selective Quenched Activity-Based Probe and Its Application in Dual Color Imaging Studies of Cathepsin S Activity Localization. Journal of the American Chemical Society, 2015, 137, 4771-4777.	6.6	63
89	PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by <sup>19</sup> F MRI. Nanomedicine, 2015, 10, 2339-2348.	1.7	34
90	Selective Expression of the MAPK Phosphatase Dusp9/MKP-4 in Mouse Plasmacytoid Dendritic Cells and Regulation of IFN-Î <sup>2</sup> Production. Journal of Immunology, 2015, 195, 1753-1762.	0.4	8

0

#	Article	IF	CITATIONS
91	Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncolmmunology, 2015, 4, e1019197.	2.1	55
92	Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment. Immunobiology, 2015, 220, 243-248.	0.8	13
93	Polymer-Based Synthetic Dendritic Cells for Tailoring Robust and Multifunctional T Cell Responses. ACS Chemical Biology, 2015, 10, 485-492.	1.6	43
94	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Frontiers in Immunology, 2014, 5, 165.	2.2	127
95	Dynamic coupling of ALCAM to the actin cortex strengthens cell adhesion to CD6. Journal of Cell Science, 2014, 127, 1595-606.	1.2	39
96	Syntenin-1 and Ezrin Proteins Link Activated Leukocyte Cell Adhesion Molecule to the Actin Cytoskeleton. Journal of Biological Chemistry, 2014, 289, 13445-13460.	1.6	34
97	Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients. American Journal of Ophthalmology, 2014, 158, 939-947.e5.	1.7	53
98	Podosomes of dendritic cells facilitate antigen sampling. Journal of Cell Science, 2014, 127, 1052-1064.	1.2	71
99	Cord Blood Mesenchymal Stem Cells Suppress DC-T Cell Proliferation via Prostaglandin B2. Stem Cells and Development, 2014, 23, 1582-1593.	1.1	16
100	Actin-binding proteins differentially regulate endothelial cell stiffness, ICAM-1 function and neutrophil transmigration. Journal of Cell Science, 2014, 127, 4985-4985.	1.2	25
101	Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy. Oncolmmunology, 2014, 3, e27219.	2.1	3
102	Tumoricidal activity of human dendritic cells. Trends in Immunology, 2014, 35, 38-46.	2.9	62
103	Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends in Biotechnology, 2014, 32, 456-465.	4.9	182
104	Actin-binding proteins differentially regulate endothelial cell stiffness, ICAM-1 function and neutrophil transmigration. Journal of Cell Science, 2014, 127, 4470-82.	1.2	89
105	The right touch: design of artificial antigen-presenting cells to stimulate the immune system. Chemical Science, 2014, 5, 3355.	3.7	41
106	Tracking Targeted Bimodal Nanovaccines: Immune Responses and Routing in Cells, Tissue, and Whole Organism. Molecular Pharmaceutics, 2014, 11, 4299-4313.	2.3	42
107	Using Magnetic Probes to Study Receptor Clustering in Live Cells. Biophysical Journal, 2014, 106, 20a.	0.2	0

108 Dendritic Cell-Based Cancer Vaccines. , 2014, , 69-87.

#	Article	IF	CITATIONS
109	Actin-binding proteins differentially regulate endothelial cell stiffness, ICAM-1 function and neutrophil transmigration. Development (Cambridge), 2014, 141, e2106-e2106.	1.2	0
110	In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cellular and Molecular Life Sciences, 2013, 70, 2237-2257.	2.4	21
111	Therapeutic nanoworms: towards novel synthetic dendritic cells for immunotherapy. Chemical Science, 2013, 4, 4168.	3.7	91
112	The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients. Cellular Oncology (Dordrecht), 2013, 36, 363-374.	2.1	56
113	ALCAM/CD166 adhesive function is regulated by the tetraspanin CD9. Cellular and Molecular Life Sciences, 2013, 70, 475-493.	2.4	61
114	Studying T-Cell Co-Receptors with Magnetic Probes. Biophysical Journal, 2013, 104, 500a-501a.	0.2	0
115	The Neck Region Regulates Spatiotemporal Organization and Virus-Binding Capability of the Pathogen Recognition Receptor DC-Sign. Biophysical Journal, 2013, 104, 610a.	0.2	0
116	Probing cellular heterogeneity in cytokine-secreting immune cells using droplet-based microfluidics. Lab on A Chip, 2013, 13, 4740.	3.1	204
117	Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion. Journal of Immunology, 2013, 191, 5005-5012.	0.4	98
118	Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood, 2013, 121, 459-467.	0.6	154
119	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination. Cancer Research, 2013, 73, 19-29.	0.4	131
120	Physical limits of cell migration: Control by ECM space and nuclear deformation and tuning by proteolysis and traction force. Journal of Cell Biology, 2013, 201, 1069-1084.	2.3	1,123
121	Mesoscale Coordinated Dynamics of Cytoskeletal Components at Mechanosensory Podosomes Shown by Time Resolved STICS. Biophysical Journal, 2013, 104, 143a.	0.2	0
122	Integrating High-Resolution Bioimaging Techniques to Unravel How Membrane Lipids Influence Nanoscale Organization and Lateral Mobility of Adhesion Receptors. Biophysical Journal, 2013, 104, 612a.	0.2	0
123	Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients. Cancer Research, 2013, 73, 1063-1075.	0.4	295
124	Dendritic cell-based nanovaccines for cancer immunotherapy. Current Opinion in Immunology, 2013, 25, 389-395.	2.4	118
125	Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. Clinical Cancer Research, 2013, 19, 1525-1533.	3.2	58
126	Interplay between myosin IIA-mediated contractility and actin network integrity orchestrates podosome composition and oscillations. Nature Communications, 2013, 4, 1412.	5.8	117

#	Article	IF	CITATIONS
127	Human Plasmacytoid Dendritic Cells: From Molecules to Intercellular Communication Network. Frontiers in Immunology, 2013, 4, 372.	2.2	93
128	<em>In vivo</em> <sup>19</sup> F MRI for Cell Tracking. Journal of Visualized Experiments, 2013, , e50802.	0.2	18
129	Dual-color superresolution microscopy reveals nanoscale organization of mechanosensory podosomes. Molecular Biology of the Cell, 2013, 24, 2112-2123.	0.9	104
130	Cell tracking using multimodal imaging. Contrast Media and Molecular Imaging, 2013, 8, 432-438.	0.4	19
131	Functional OCT4-specific CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells in healthy controls and ovarian cancer patients. Oncolmmunology, 2013, 2, e24271.	2.1	11
132	Automated Podosome Identification and Characterization in Fluorescence Microscopy Images. Microscopy and Microanalysis, 2013, 19, 180-189.	0.2	18
133	Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination. Oncolmmunology, 2013, 2, e24661.	2.1	20
134	Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. Oncolmmunology, 2013, 2, e24440.	2.1	11
135	Naturally circulating dendritic cells to vaccinate cancer patients. Oncolmmunology, 2013, 2, e23431.	2.1	27
136	Targeting dendritic cells—why bother?. Blood, 2013, 121, 2836-2844.	0.6	106
137	The nature of activatory and tolerogenic dendritic cell-derived signal II. Frontiers in Immunology, 2013, 4, 53.	2.2	91
138	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Frontiers in Immunology, 2013, 4, 417.	2.2	62
139	Aiming to immune elimination of ovarian cancer stem cells. World Journal of Stem Cells, 2013, 5, 149.	1.3	6
140	Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts. , 2013, , 71-108.		0
141	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clinical Cancer Research, 2012, 18, 5460-5470.	3.2	86
142	Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by <i>in vivo</i> targeting to dendritic cells. Nanomedicine, 2012, 7, 1591-1610.	1.7	5
143	The Neck Region of the C-type Lectin DC-SIGN Regulates Its Surface Spatiotemporal Organization and Virus-binding Capacity on Antigen-presenting Cells. Journal of Biological Chemistry, 2012, 287, 38946-38955.	1.6	52
144	Lateral mobility of individual integrin nanoclusters orchestrates the onset for leukocyte adhesion. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4869-4874.	3.3	86

#	Article	IF	CITATIONS
145	In Vivo Tracking Techniques for Cellular Regeneration, Replacement, and Redirection. Journal of Nuclear Medicine, 2012, 53, 1825-1828.	2.8	19
146	The Tetraspanin CD37 Orchestrates the α <sub>4</sub> β <sub>1</sub> Integrin–Akt Signaling Axis and Supports Long-Lived Plasma Cell Survival. Science Signaling, 2012, 5, ra82.	1.6	89
147	The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood, 2012, 119, 2284-2292.	0.6	217
148	Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncology, The, 2012, 13, e32-e42.	5.1	219
149	Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood, 2012, 120, 3936-3944.	0.6	80
150	Integrating High Resolution Bioimaging Techniques to Unravel Spatio-Temporal Organization of Podosomes. Biophysical Journal, 2012, 102, 695a.	0.2	0
151	Deciphering the Cross-Talk of the Prostaglandin G-Protein Coupled Receptors EP2 and EP4: From Molecular Insights to Novel Anti-Tumor Targets. Biophysical Journal, 2012, 102, 517a.	0.2	0
152	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma. Cancer Research, 2012, 72, 6102-6110.	0.4	50
153	Antibodies and carbohydrate ligands binding to <scp>DCâ€6IGN</scp> differentially modulate receptor trafficking. European Journal of Immunology, 2012, 42, 1989-1998.	1.6	25
154	Targeting dendritic cells with antigen via dendritic cell-associated promoters. Cancer Gene Therapy, 2012, 19, 303-311.	2.2	14
155	Labeling cells for inÂvivo tracking using 19F MRI. Biomaterials, 2012, 33, 8830-8840.	5.7	126
156	A Method for Spatially Resolved Local Intracellular Mechanochemical Sensing and Organelle Manipulation. Biophysical Journal, 2012, 103, 395-404.	0.2	10
157	Targeting Nanoparticles to Dendritic Cells for Immunotherapy. Methods in Enzymology, 2012, 509, 143-163.	0.4	110
158	Insight into the dynamics, localization and magnitude of antigen-specific immune responses by [18F]FLT PET imaging. Oncolmmunology, 2012, 1, 744-745.	2.1	3
159	Geometry sensing by dendritic cells dictates spatial organization and PGE2-induced dissolution of podosomes. Cellular and Molecular Life Sciences, 2012, 69, 1889-1901.	2.4	72
160	The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunology, Immunotherapy, 2012, 61, 1101-1111.	2.0	41
161	Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunology, Immunotherapy, 2012, 61, 1279-1288.	2.0	53
162	Current Vaccination Strategies for Prostate Cancer. European Urology, 2012, 61, 290-306.	0.9	35

#	Article	IF	CITATIONS
163	Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials, 2012, 33, 4229-4239.	5.7	71
164	Unraveling the human dendritic cell phagosome proteome by organellar enrichment ranking. Journal of Proteomics, 2012, 75, 1547-1562.	1.2	27
165	A largeâ€scale <sup>19</sup> F MRIâ€based cell migration assay to optimize cell therapy. NMR in Biomedicine, 2012, 25, 1095-1103.	1.6	20
166	The Modular Nature of Dendritic Cell Responses to Commensal and Pathogenic Fungi. PLoS ONE, 2012, 7, e42430.	1.1	12
167	Dynamic cell adhesion and migration on nanoscale grooved substrates. , 2012, 23, 182-194.		53
168	Novel Concepts in Dendritic Cell Vaccination against Cancer. AACR Education Book, 2012, 2012, 61-65.	0.0	0
169	Multimodal Imaging of Nanovaccine Carriers Targeted to Human Dendritic Cells. Molecular Pharmaceutics, 2011, 8, 520-531.	2.3	70
170	Cytokine analysis as a tool to understand tumour–host interaction in ovarian cancer. European Journal of Cancer, 2011, 47, 1883-1889.	1.3	46
171	Targeted antigen delivery and activation of dendritic cells in vivo: Steps towards cost effective vaccines. Seminars in Immunology, 2011, 23, 12-20.	2.7	118
172	Cytokine Profiles in Cyst Fluids From Ovarian Tumors Reflect Immunosuppressive State of the Tumor. International Journal of Gynecological Cancer, 2011, 21, 1241-1247.	1.2	14
173	Infection of dendritic cells with herpes simplex virus type 1 induces rapid degradation of CYTIP, thereby modulating adhesion and migration. Blood, 2011, 118, 107-115.	0.6	36
174	Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood, 2011, 118, 4111-4119.	0.6	104
175	Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood, 2011, 118, 6836-6844.	0.6	155
176	The lymphoid chemokine CCL21 triggers LFAâ€₁ adhesive properties on human dendritic cells. Immunology and Cell Biology, 2011, 89, 458-465.	1.0	15
177	Interlaboratory round robin on cantilever calibration for AFM force spectroscopy. Ultramicroscopy, 2011, 111, 1659-1669.	0.8	110
178	Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Molecular Immunology, 2011, 48, 810-817.	1.0	24
179	The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials, 2011, 32, 6791-6803.	5.7	167
180	Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients. Clinical Cancer Research, 2011, 17, 5725-5735.	3.2	158

#	Article	IF	CITATIONS
181	Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunology, Immunotherapy, 2011, 60, 249-260.	2.0	68
182	DECâ€205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. European Journal of Immunology, 2011, 41, 1014-1023.	1.6	63
183	A novel <sup>19</sup> F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. International Journal of Cancer, 2011, 129, 365-373.	2.3	61
184	IL-4 and IL-13 Alter Plasmacytoid Dendritic Cell Responsiveness to CpG DNA and Herpes Simplex Virus-1. Journal of Investigative Dermatology, 2011, 131, 900-906.	0.3	19
185	Antigen Localization Controls T Cell-Mediated Tumor Immunity. Journal of Immunology, 2011, 187, 1281-1288.	0.4	39
186	Early identification of antigen-specific immune responses in vivo by [ <sup>18</sup> F]-labeled 3′-fluoro-3′-deoxy-thymidine ([ <sup>18</sup> F]FLT) PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18396-18399.	3.3	65
187	Immune Adjuvant Efficacy of CpG Oligonucleotide in Cancer Treatment Is Founded Specifically upon TLR9 Function in Plasmacytoid Dendritic Cells. Cancer Research, 2011, 71, 6428-6437.	0.4	99
188	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. Journal of Clinical Investigation, 2011, 121, 3100-3108.	3.9	271
189	Eradicating cancer cells: struggle with a chameleon. Oncotarget, 2011, 2, 99-101.	0.8	14
190	Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood, 2010, 116, 564-574.	0.6	86
191	Imaging of cellular therapies. Advanced Drug Delivery Reviews, 2010, 62, 1080-1093.	6.6	126
192	Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunology, Immunotherapy, 2010, 59, 1573-1582.	2.0	220
193	Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials, 2010, 31, 7070-7077.	5.7	120
194	Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. Journal of Controlled Release, 2010, 144, 118-126.	4.8	242
195	19F MRI for quantitative in vivo cell tracking. Trends in Biotechnology, 2010, 28, 363-370.	4.9	252
196	Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecologic Oncology, 2010, 117, 366-372.	0.6	134
197	The role of tetraspanins in the pathogenesis of infectious diseases. Microbes and Infection, 2010, 12, 106-112.	1.0	68
198	Spatially resolved local intracellular chemical sensing using magnetic particles. Sensors and Actuators B: Chemical, 2010, 148, 531-538.	4.0	10

#	Article	IF	CITATIONS
199	Dendritic Cell Subsets Digested: RNA Sensing Makes the Difference!. Immunity, 2010, 32, 149-151.	6.6	5
200	A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. British Journal of Cancer, 2010, 103, 1415-1421.	2.9	60
201	Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients. Clinical Cancer Research, 2010, 16, 5067-5078.	3.2	212
202	Human Plasmacytoid Dendritic Cells Phagocytose, Process, and Present Exogenous Particulate Antigen. Journal of Immunology, 2010, 184, 4276-4283.	0.4	80
203	Hematopoietic Stem Cells Are Coordinated by the Molecular Cues of the Endosteal Niche. Stem Cells and Development, 2010, 19, 1131-1141.	1.1	16
204	TLR4-Mediated Podosome Loss Discriminates Gram-Negative from Gram-Positive Bacteria in Their Capacity to Induce Dendritic Cell Migration and Maturation. Journal of Immunology, 2010, 184, 1280-1291.	0.4	33
205	Hotspots of GPI-Anchored Proteins and Integrin Nanoclusters Function as Nucleation Sites for Cell Adhesion. Biophysical Journal, 2010, 98, 577a.	0.2	1
206	A FRET-FLIM Study Reveals the Interaction between ALCAM and Actin as a Potential Regulator of ALCAM Binding Activity. Biophysical Journal, 2010, 98, 748a.	0.2	0
207	Functional Differences Between Mesenchymal Stem Cell Populations Are Reflected by Their Transcriptome. Stem Cells and Development, 2010, 19, 481-490.	1.1	124
208	DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells. Immunome Research, 2010, 6, 10.	0.1	23
209	Molecular Friction as a Tool to Identify Functionalized Alkanethiols. Langmuir, 2010, 26, 6357-6366.	1.6	27
210	Dominant Processes during Human Dendritic Cell Maturation Revealed by Integration of Proteome and Transcriptome at the Pathway Level. Journal of Proteome Research, 2010, 9, 1727-1737.	1.8	45
211	Fungal pattern-recognition receptors and tetraspanins: partners on antigen-presenting cells. Trends in Immunology, 2010, 31, 91-96.	2.9	22
212	The Tetraspanin CD37 Protects Against Glomerular IgA Deposition and Renal Pathology. American Journal of Pathology, 2010, 176, 2188-2197.	1.9	23
213	Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1383-1390.	2.5	131
214	AFM topography and friction studies of hydrogen-bonded bilayers of functionalized alkanethiols. Soft Matter, 2010, 6, 3450.	1.2	8
215	Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Research, 2010, 30, 5091-7.	0.5	67
216	Hotspots of GPI-anchored proteins and integrin nanoclusters function as nucleation sites for cell adhesion. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18557-18562.	3.3	217

#	Article	IF	CITATIONS
217	In situ Expression of Tumor Antigens by Messenger RNA–Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients. Cancer Research, 2009, 69, 2927-2934.	0.4	56
218	Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients. Clinical Cancer Research, 2009, 15, 2531-2540.	3.2	172
219	The Tetraspanin Protein CD37 Regulates IgA Responses and Anti-Fungal Immunity. PLoS Pathogens, 2009, 5, e1000338.	2.1	73
220	DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. Journal of Leukocyte Biology, 2009, 85, 518-525.	1.5	125
221	Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1036-1043.	0.5	22
222	Toll-like receptor triggering in cord blood mesenchymal stem cells. Journal of Cellular and Molecular Medicine, 2009, 13, 3415-3426.	1.6	49
223	Necrosis: C-Type Lectins Sense Cell Death. Current Biology, 2009, 19, R375-R378.	1.8	53
224	The Câ€ŧype lectin DCâ€5IGN internalizes soluble antigens and HIVâ€1 virions <i>via</i> a clathrinâ€dependent mechanism. European Journal of Immunology, 2009, 39, 1923-1928.	1.6	60
225	Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunology, Immunotherapy, 2009, 58, 145-151.	2.0	29
226	Targets for active immunotherapy against pediatric solid tumors. Cancer Immunology, Immunotherapy, 2009, 58, 831-841.	2.0	10
227	Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunology, Immunotherapy, 2009, 58, 1109-1115.	2.0	25
228	Dynamic Reâ€organization of Individual Adhesion Nanoclusters in Living Cells by Ligandâ€Patterned Surfaces. Small, 2009, 5, 1258-1263.	5.2	12
229	Cord blood mesenchymal stem cells propel human dendritic cells to an intermediate maturation state and boost interleukinâ€12 production by mature dendritic cells. Immunology, 2009, 128, 564-572.	2.0	23
230	A hybrid total internal reflection fluorescence and optical tweezers microscope to study cell adhesion and membrane protein dynamics of single living cells. Journal of Microscopy, 2009, 233, 84-92.	0.8	12
231	Dendritic cell vaccination and immune monitoring. ISBT Science Series, 2009, 4, 18-23.	1.1	0
232	<i>In Vivo</i> Recruitment of Hematopoietic Cells Using Stromal Cell–Derived Factor 1 Alpha–Loaded Heparinized Three-Dimensional Collagen Scaffolds. Tissue Engineering - Part A, 2009, 15, 1591-1599.	1.6	39
233	Mesenchymal stem cells respond to TNF but do not produce TNF. Journal of Leukocyte Biology, 2009, 87, 283-289.	1.5	46
234	Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice. PLoS ONE, 2009, 4, e8368.	1.1	90

#	Article	IF	CITATIONS
235	Human and murine model cell lines for dendritic cell biology evaluated. Immunology Letters, 2008, 117, 191-197.	1.1	59
236	Selective cancer-germline gene expression in pediatric brain tumors. Journal of Neuro-Oncology, 2008, 88, 273-280.	1.4	24
237	Mesenchymal stromal cells: tissue engineers and immune response modulators. Archivum Immunologiae Et Therapiae Experimentalis, 2008, 56, 325-329.	1.0	7
238	Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunology, Immunotherapy, 2008, 57, 1589-1597.	2.0	141
239	Dendritic cell vaccination and immune monitoring. Cancer Immunology, Immunotherapy, 2008, 57, 1559-1568.	2.0	91
240	Manufacturing substrate nano-grooves for studying cell alignment and adhesion. Microelectronic Engineering, 2008, 85, 1362-1366.	1.1	44
241	Dendritic cell vaccines in melanoma: From promise to proof?. Critical Reviews in Oncology/Hematology, 2008, 66, 118-134.	2.0	113
242	The DC-derived protein DC-STAMP influences differentiation of myeloid cells. Leukemia, 2008, 22, 455-459.	3.3	10
243	Interaction of acute lymphopblastic leukemia cells with C-type lectins DC-SIGN and L-SIGN. Experimental Hematology, 2008, 36, 860-870.	0.2	12
244	The αâ€kinases TRPM6 and TRPM7, but not eEFâ€⊋ kinase, phosphorylate the assembly domain of myosin IIA, IIB and IIC. FEBS Letters, 2008, 582, 2993-2997.	1.3	74
245	TRPM7 Regulates Myosin IIA Filament Stability and Protein Localization by Heavy Chain Phosphorylation. Journal of Molecular Biology, 2008, 378, 790-803.	2.0	125
246	Maximizing dendritic cell migration in cancer immunotherapy. Expert Opinion on Biological Therapy, 2008, 8, 865-874.	1.4	59
247	Monocyte Cell Surface Glycosaminoglycans Positively Modulate IL-4-Induced Differentiation toward Dendritic Cells. Journal of Immunology, 2008, 180, 3680-3688.	0.4	49
248	Dendritic Cell Interaction with Candida albicans Critically Depends on N-Linked Mannan. Journal of Biological Chemistry, 2008, 283, 20590-20599.	1.6	209
249	No Advantage of Cell-Penetrating Peptides over Receptor-Specific Antibodies in Targeting Antigen to Human Dendritic Cells for Cross-Presentation. Journal of Immunology, 2008, 180, 7687-7696.	0.4	40
250	Activation of Human Plasmacytoid Dendritic Cells by TLR9 Impairs FcÎ <sup>3</sup> RII-Mediated Uptake of Immune Complexes and Presentation by MHC Class II. Journal of Immunology, 2008, 181, 5219-5224.	0.4	24
251	<i>In vivo</i> Colocalization of Antigen and CpG within Dendritic Cells Is Associated with the Efficacy of Cancer Immunotherapy. Cancer Research, 2008, 68, 5390-5396.	0.4	55
252	PGE2-mediated podosome loss in dendritic cells is dependent on actomyosin contraction downstream of the RhoA–Rho-kinase axis. Journal of Cell Science, 2008, 121, 1096-1106.	1.2	82

#	Article	IF	CITATIONS
253	Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production. Blood, 2008, 111, 4245-4253.	0.6	230
254	Massive Autophosphorylation of the Ser/Thr-Rich Domain Controls Protein Kinase Activity of TRPM6 and TRPM7. PLoS ONE, 2008, 3, e1876.	1.1	88
255	Dectin-1 Interaction with Tetraspanin CD37 Inhibits IL-6 Production. Journal of Immunology, 2007, 178, 154-162.	0.4	96
256	Distinct kinetic and mechanical properties govern ALCAM-mediated interactions as shown by single-molecule force spectroscopy. Journal of Cell Science, 2007, 120, 3965-3976.	1.2	38
257	Relevance of DC-SIGN in DC-induced T cell proliferation. Journal of Leukocyte Biology, 2007, 81, 729-740.	1.5	24
258	In Vivo Targeting of DC-SIGN-positive Antigen-presenting Cells in a Nonhuman Primate Model. Journal of Immunotherapy, 2007, 30, 705-714.	1.2	31
259	Binding of the adhesion and pathogen receptor DC-SIGN by monocytes is regulated by the density of Lewis X molecules. Molecular Immunology, 2007, 44, 2481-2486.	1.0	4
260	Ligand-Conjugated Quantum Dots Monitor Antigen Uptake and Processing by Dendritic Cells. Nano Letters, 2007, 7, 970-977.	4.5	105
261	Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. International Journal of Cancer, 2007, 120, 67-74.	2.3	70
262	Nanoscale Organization of the Pathogen Receptor DC-SIGN Mapped by Single-Molecule High-Resolution Fluorescence Microscopy. ChemPhysChem, 2007, 8, 1473-1480.	1.0	93
263	Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediatric Blood and Cancer, 2007, 49, 924-927.	0.8	10
264	Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Reviews Immunology, 2007, 7, 790-802.	10.6	678
265	Potential applications of dendritic cells. ISBT Science Series, 2007, 2, 264-271.	1.1	0
266	Myosin II and mechanotransduction: a balancing act. Trends in Cell Biology, 2007, 17, 178-186.	3.6	193
267	In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunology, Immunotherapy, 2007, 56, 1667-1676.	2.0	24
268	The threshold at which substrate nanogroove dimensions may influence fibroblast alignment and adhesion. Biomaterials, 2007, 28, 3944-3951.	5.7	311
269	Detection of Fungi by Mannose-based Recognition Receptors. , 2007, , 293-307.		5
270	Ex Vivo–Generated Dendritic Cells for ClinicalTrials versus In Vivo Targeting to Dendritic Cells: Critical Issues. , 2007, , 203-242.		0

#	Article	IF	CITATIONS
271	Targeting antigens to dendritic cells in vivo. Immunobiology, 2006, 211, 599-608.	0.8	112
272	Development of 1111n-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination. Nuclear Medicine and Biology, 2006, 33, 453-458.	0.3	14
273	Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood, 2006, 107, 3212-3220.	0.6	185
274	Closing in on Toll-like receptors and NOD-LRR proteins in inflammatory disorders. Future Rheumatology, 2006, 1, 465-479.	0.2	2
275	TRPM7, a novel regulator of actomyosin contractility and cell adhesion. EMBO Journal, 2006, 25, 290-301.	3.5	323
276	Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. International Journal of Cancer, 2006, 120, 978-984.	2.3	82
277	Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Annals of Oncology, 2006, 17, 974-980.	0.6	85
278	C-Type Lectins on Dendritic Cells and Their Interaction with Pathogen-Derived and Endogenous Glycoconjugates. Current Protein and Peptide Science, 2006, 7, 283-294.	0.7	22
279	A Critical Role for Prostaglandin E2 in Podosome Dissolution and Induction of High-Speed Migration during Dendritic Cell Maturation. Journal of Immunology, 2006, 177, 1567-1574.	0.4	133
280	Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after FcγRII-mediated uptake. Journal of Experimental Medicine, 2006, 203, 1629-1635.	4.2	92
281	Internalizing Antibodies to the C-Type Lectins, L-SIGN and DC-SIGN, Inhibit Viral Glycoprotein Binding and Deliver Antigen to Human Dendritic Cells for the Induction of T Cell Responses. Journal of Immunology, 2006, 176, 426-440.	0.4	51
282	Organization of the Integrin LFA-1 in Nanoclusters Regulates Its Activity. Molecular Biology of the Cell, 2006, 17, 4270-4281.	0.9	118
283	Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell Vaccine. Cancer Research, 2006, 66, 7285-7292.	0.4	166
284	Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. British Journal of Cancer, 2006, 95, 896-905.	2.9	248
285	Phenotypical and Functional Characterization of Clinical-Grade Dendritic Cells. , 2005, 109, 113-126.		28
286	Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti–DC-SIGN antibody. Blood, 2005, 106, 1278-1285.	0.6	265
287	Levels of complexity in pathogen recognition by C-type lectins. Current Opinion in Immunology, 2005, 17, 345-351.	2.4	72
288	Near-Field Fluorescence Microscopy: An Optical Nanotool to Study Protein Organization at the Cell Membrane. Nanobiotechnology, 2005, 1, 113-120.	1.2	21

#	Article	IF	CITATIONS
289	How C-type lectins detect pathogens. Cellular Microbiology, 2005, 7, 481-488.	1.1	355
290	Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nature Biotechnology, 2005, 23, 1407-1413.	9.4	791
291	Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis and Rheumatism, 2005, 52, 1381-1391.	6.7	128
292	Migration of dendritic cell based cancer vaccines: in vivo veritas?. Current Opinion in Immunology, 2005, 17, 170-174.	2.4	135
293	Dendritic cells: tools and targets for antitumor vaccination. Expert Review of Vaccines, 2005, 4, 699-710.	2.0	45
294	Novel monoclonal antibodies detect elevated levels of the chemokine CCL18/DC-CK1 in serum and body fluids in pathological conditions. Journal of Leukocyte Biology, 2005, 77, 739-747.	1.5	16
295	Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome. Journal of Clinical Oncology, 2005, 23, 5779-5787.	0.8	174
296	The dendritic cell-derived protein DC-STAMP is highly conserved and localizes to the endoplasmic reticulum. Journal of Leukocyte Biology, 2005, 77, 337-343.	1.5	33
297	"Sweet Talk― Closing in on C Type Lectin Signaling. Immunity, 2005, 22, 399-400.	6.6	26
298	Cytoskeletal restraints regulate homotypic ALCAM-mediated adhesion through PKCα independently of Rho-like GTPases. Journal of Cell Science, 2004, 117, 2841-2852.	1.2	46
299	Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors. Annals of the Rheumatic Diseases, 2004, 64, 359-367.	0.5	76
300	Increased FcÂRII expression and aberrant tumour necrosis factor  production by mature dendritic cells from patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2004, 63, 1556-1563.	0.5	43
301	Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. Journal of Cell Biology, 2004, 164, 145-155.	2.3	222
302	In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity. Cancer Research, 2004, 64, 4024-4029.	0.4	376
303	Dendritic cell immunotherapy: mapping the way. Nature Medicine, 2004, 10, 475-480.	15.2	896
304	Differentiating Stem Cells Mask Their Origins. Stem Cells, 2004, 22, 250-252.	1.4	5
305	Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells. Journal of Pathology, 2004, 202, 70-79.	2.1	23
306	Human dendritic cells are less potent at killing Candida albicans than both monocytes and macrophages. Microbes and Infection, 2004, 6, 985-989.	1.0	53

#	Article	IF	CITATIONS
307	Current issues in delivering DCs for immunotherapy. Cytotherapy, 2004, 6, 105-110.	0.3	18
308	Near-field scanning optical microscopy in liquid for high resolution single molecule detection on dendritic cells. FEBS Letters, 2004, 573, 6-10.	1.3	104
309	NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood, 2004, 104, 3267-3275.	0.6	291
310	Dual function of C-type lectin-like receptors in the immune system. Current Opinion in Cell Biology, 2003, 15, 539-546.	2.6	225
311	An automated multi well cell track system to study leukocyte migration. Journal of Immunological Methods, 2003, 280, 89-102.	0.6	24
312	The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. European Journal of Immunology, 2003, 33, 532-538.	1.6	336
313	Expression of the dendritic cell-associated C-type lectin DC-SIGN by inflammatory matrix metalloproteinase-producing macrophages in rheumatoid arthritis synovium and interaction with intercellular adhesion molecule 3-positive T cells. Arthritis and Rheumatism, 2003, 48, 360-369.	6.7	43
314	Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunology Letters, 2003, 89, 17-24.	1.1	43
315	Ceramic hydroxyapatite coating on titanium implants drives selective bone marrow stromal cell adhesion. Clinical Oral Implants Research, 2003, 14, 569-577.	1.9	11
316	Dual function of C-type lectin-like receptors in the immune system. Current Opinion in Cell Biology, 2003, 15, 539-539.	2.6	11
317	Different Faces of the Heme-Heme Oxygenase System in Inflammation. Pharmacological Reviews, 2003, 55, 551-571.	7.1	503
318	Molecular characterization of dendritic cells operating at the interface of innate of acquired immunity. Pathologie Et Biologie, 2003, 51, 61-63.	2.2	13
319	Peptide Fine Specificity of Anti-Glycoprotein 100 CTL Is Preserved Following Transfer of Engineered TCRαβ Genes Into Primary Human T Lymphocytes. Journal of Immunology, 2003, 170, 2186-2194.	0.4	138
320	The heme-heme oxygenase system: a molecular switch in wound healing. Blood, 2003, 102, 521-528.	0.6	122
321	State of the Art in Dendritic Cell Vaccination. , 2003, , 153-159.		0
322	Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Research, 2003, 63, 12-7.	0.4	659
323	Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clinical Cancer Research, 2003, 9, 5091-100.	3.2	235
324	The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells. Journal of Immunology, 2002, 168, 2118-2126.	0.4	568

#	Article	IF	CITATIONS
325	Identification of Different Binding Sites in the Dendritic Cell-specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1. Journal of Biological Chemistry, 2002, 277, 11314-11320.	1.6	165
326	The Small GTPase Rap1 Is Required for Mn2+- and Antibody-induced LFA-1- and VLA-4-mediated Cell Adhesion. Journal of Biological Chemistry, 2002, 277, 29468-29476.	1.6	98
327	Phenotypical and Functional Characterization of Clinical Grade Dendritic Cells. Journal of Immunotherapy, 2002, 25, 429-438.	1.2	140
328	Enhancement of G-CSF–induced stem cell mobilization by antibodies against the β2 integrins LFA-1 and Mac-1. Blood, 2002, 100, 327-333.	0.6	42
329	Modulation of Integrin Expression on Rat Bone Marrow Cells by Substrates with Different Surface Characteristics. Tissue Engineering, 2002, 8, 615-626.	4.9	37
330	The Achilles' heel of HIV. Medical Hypotheses, 2002, 58, 386-387.	0.8	5
331	Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-dr molecules to CD4+ T lymphocytes. International Journal of Cancer, 2002, 100, 441-444.	2.3	49
332	C-type lectin receptors on dendritic cells and langerhans cells. Nature Reviews Immunology, 2002, 2, 77-84.	10.6	750
333	Heme-induced cell adhesion in the pathogenesis of sickle-cell disease and inflammation. Trends in Pharmacological Sciences, 2001, 22, 52-54.	4.0	64
334	DC-SIGN and LFA-1: a battle for ligand. Trends in Immunology, 2001, 22, 457-463.	2.9	71
335	The Extracellular Domain of CD83 Inhibits Dendritic Cell–mediated T Cell Stimulation and Binds to a Ligand on Dendritic Cells. Journal of Experimental Medicine, 2001, 194, 1813-1821.	4.2	168
336	Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood, 2001, 98, 1802-1811.	0.6	383
337	Genomic organization, chromosomal localization, and 5′ upstream region of the human DC-STAMP gene. Immunogenetics, 2001, 53, 145-149.	1.2	15
338	Expression of leukocyte adhesion molecules by endothelial cells seeded on various polymer surfaces. Journal of Biomedical Materials Research Part B, 2001, 56, 376-381.	3.0	20
339	BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. European Journal of Immunology, 2001, 31, 1544-1549.	1.6	87
340	TCRγδ cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplantation, 2001, 27, 1087-1093.	1.3	51
341	DC-SIGN, a Dentritic Cell-Specific HIV-1 Receptor Present in Placenta That Infects T Cells In Trans—A Review. Placenta, 2001, 22, S19-S23.	0.7	42
342	The Dendritic Cell-Specific CC-Chemokine DC-CK1 Is Expressed by Germinal Center Dendritic Cells and Attracts CD38-Negative Mantle Zone B Lymphocytes. Journal of Immunology, 2001, 166, 3284-3289.	0.4	66

#	Article	IF	CITATIONS
343	A Single Amino Acid in the Cytoplasmic Domain of the β2 Integrin Lymphocyte Function-associated Antigen-1 Regulates Avidity-dependent Inside-out Signaling. Journal of Biological Chemistry, 2001, 276, 10338-10346.	1.6	24
344	Molecular Basis for the Homophilic Activated Leukocyte Cell Adhesion Molecule (ALCAM)-ALCAM Interaction. Journal of Biological Chemistry, 2001, 276, 25783-25790.	1.6	137
345	Cell biology beyond the diffraction limit: near-field scanning optical microscopy. Journal of Cell Science, 2001, 114, 4153-4160.	1.2	184
346	Quantitative analysis of chemokine expression by dendritic cell subsets in vitro and in vivo. Journal of Leukocyte Biology, 2001, 69, 785-93.	1.5	67
347	Cell biology beyond the diffraction limit: near-field scanning optical microscopy. Journal of Cell Science, 2001, 114, 4153-60.	1.2	130
348	Regulation of LFA-1 Expression by CD34 Positive Cells and Inducible Growth Factor Production by Stroma Enable Formation of Bone Marrow Compartments. Hematology, 2000, 5, 295-302.	0.7	2
349	Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. , 2000, 85, 865-870.		152
350	DC-STAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells. European Journal of Immunology, 2000, 30, 3585-3590.	1.6	101
351	Towards a molecular understanding of dendritic cell immunobiology. Trends in Immunology, 2000, 21, 542-545.	7.5	55
352	DC-SIGN–ICAM-2 interaction mediates dendritic cell trafficking. Nature Immunology, 2000, 1, 353-357.	7.0	465
353	Molecular analysis of the hematopoiesis supporting osteoblastic cell line U2-OS. Experimental Hematology, 2000, 28, 422-432.	0.2	67
354	Avidity regulation of integrins: the driving force in leukocyte adhesion. Current Opinion in Cell Biology, 2000, 12, 542-547.	2.6	320
355	The LFA-1 Integrin Supports Rolling Adhesions on ICAM-1 Under Physiological Shear Flow in a Permissive Cellular Environment. Journal of Immunology, 2000, 165, 442-452.	0.4	113
356	Dynamic Regulation of Activated Leukocyte Cell Adhesion Molecule–mediated Homotypic Cell Adhesion through the Actin Cytoskeleton. Molecular Biology of the Cell, 2000, 11, 2057-2068.	0.9	71
357	Biomolecular Interactions Measured by Atomic Force Microscopy. Biophysical Journal, 2000, 79, 3267-3281.	0.2	226
358	The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem-cell mobilization. Seminars in Hematology, 2000, 37, 19-24.	1.8	52
359	Identification of DC-SIGN, a Novel Dendritic Cell–Specific ICAM-3 Receptor that Supports Primary Immune Responses. Cell, 2000, 100, 575-585.	13.5	1,558
360	DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells. Cell, 2000, 100, 587-597.	13.5	2,214

#	Article	IF	CITATIONS
361	Cytohesin-1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with LFA-1. EMBO Journal, 2000, 19, 2525-2536.	3.5	132
362	Dendritic Cell-Based Vaccines: From Mouse Models to Clinical Cancer Immunotherapy. Critical Reviews in Oncogenesis, 2000, 11, 17.	0.2	28
363	Low-affinity LFA-1/ICAM-3 interactions augment LFA-1/ICAM-1-mediated T cell adhesion and signaling by redistribution of LFA-1. Journal of Cell Science, 2000, 113 ( Pt 3), 391-400.	1.2	11
364	Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Research, 2000, 60, 6995-7001.	0.4	103
365	Murine Hematopoietic Progenitor Cells With Colony-Forming or Radioprotective Capacity Lack Expression of the β2-Integrin LFA-1. Blood, 1999, 93, 107-112.	0.6	32
366	High Frequency of Adhesion Defects in B-Lineage Acute Lymphoblastic Leukemia. Blood, 1999, 94, 754-764.	0.6	99
367	A Human Minor Histocompatibility Antigen Specific for B Cell Acute Lymphoblastic Leukemia. Journal of Experimental Medicine, 1999, 189, 301-308.	4.2	207
368	The Actin Cytoskeleton Regulates LFA-1 Ligand Binding through Avidity Rather than Affinity Changes. Journal of Biological Chemistry, 1999, 274, 26869-26877.	1.6	139
369	Optimization of adhesion mode atomic force microscopy resolves individual molecules in topography and adhesion. Ultramicroscopy, 1999, 80, 133-144.	0.8	11
370	Integrin mediated adhesion of mononuclear cells from patients with familial hypercholesterolemia. European Journal of Clinical Investigation, 1999, 29, 749-757.	1.7	8
371	Biology of IL-8-Induced Stem Cell Mobilization. Annals of the New York Academy of Sciences, 1999, 872, 71-82.	1.8	69
372	Co-stimulation of T cells results in distinct IL-10 and TNF-α cytokine profiles dependent on binding to ICAM-1, ICAM-2 or ICAM-3. European Journal of Immunology, 1999, 29, 2248-2258.	1.6	50
373	Generation and functional characterization of mouse monocyte-derived dendritic cells. European Journal of Immunology, 1999, 29, 2835-2841.	1.6	79
374	3D single-particle tracking and optical trap measurements on adhesion proteins. , 1999, 36, 189-194.		33
375	A Physical Approach to Reduce Nonspecific Adhesion in Molecular Recognition Atomic Force Microscopy. Biophysical Journal, 1999, 76, 716-724.	0.2	43
376	High Frequency of Adhesion Defects in B-Lineage Acute Lymphoblastic Leukemia. Blood, 1999, 94, 754-764.	0.6	8
377	Murine Hematopoietic Progenitor Cells With Colony-Forming or Radioprotective Capacity Lack Expression of the β2-Integrin LFA-1. Blood, 1999, 93, 107-112.	0.6	3
378	High frequency of adhesion defects in B-lineage acute lymphoblastic leukemia. Blood, 1999, 94, 754-64.	0.6	31

#	Article	IF	CITATIONS
379	Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Research, 1999, 59, 3340-5.	0.4	219
380	The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Research, 1999, 59, 5554-9.	0.4	103
381	H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. Journal of Immunology, 1999, 163, 6209-16.	0.4	57
382	3D single-particle tracking and optical trap measurements on adhesion proteins. Cytometry, 1999, 36, 189-94.	1.8	15
383	Different growth behaviour of human umbilical vein endothelial cells and an endothelial cell line seeded on various polymer surfaces. Biomaterials, 1998, 19, 2285-2290.	5.7	21
384	Adhesion and Signaling Mediated by the Cytoplasmic Tails of Leucocyte Integrins. Cell Adhesion and Communication, 1998, 6, 247-254.	1.7	8
385	Simultaneous Height and Adhesion Imaging of Antibody-Antigen Interactions by Atomic Force Microscopy. Biophysical Journal, 1998, 75, 2220-2228.	0.2	198
386	Three dimensional single-particle tracking with nanometer resolution. Review of Scientific Instruments, 1998, 69, 2762-2766.	0.6	57
387	Dendritic Cells: Migratory Cells that are Attractive. Cell Adhesion and Communication, 1998, 6, 117-123.	1.7	9
388	Constitutive Chemokine Production Results in Activation of Leukocyte Function-Associated Antigen-1 on Adult T-Cell Leukemia Cells. Blood, 1998, 91, 3909-3919.	0.6	75
389	Anti–LFA-1 Blocking Antibodies Prevent Mobilization of Hematopoietic Progenitor Cells Induced by Interleukin-8. Blood, 1998, 91, 4099-4105.	0.6	70
390	Constitutive Chemokine Production Results in Activation of Leukocyte Function-Associated Antigen-1 on Adult T-Cell Leukemia Cells. Blood, 1998, 91, 3909-3919.	0.6	6
391	Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. Journal of Immunology, 1998, 160, 5239-45.	0.4	104
392	Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Research, 1998, 58, 2509-14.	0.4	52
393	Dual role of the actin cytoskeleton in regulating cell adhesion mediated by the integrin lymphocyte function-associated molecule-1 Molecular Biology of the Cell, 1997, 8, 341-351.	0.9	158
394	Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineagespecific antigen gp100. Melanoma Research, 1997, 7, 463-470.	0.6	19
395	Cytoplasmic tails of beta 1, beta 2, and beta 7 integrins differentially regulate LFA-1 function in K562 cells Molecular Biology of the Cell, 1997, 8, 719-728.	0.9	49
396	Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage. British Journal of Cancer, 1997, 76, 1562-1566.	2.9	39

#	Article	lF	CITATIONS
397	Carotenoid levels in human lymphocytes, measured by Raman microspectroscopy. Pure and Applied Chemistry, 1997, 69, 2131-2134.	0.9	21
398	Targeted immunotherapy: Dendritic cells to present tumor-associated antigens. European Journal of Cancer, 1997, 33, S291.	1.3	0
399	Signalling and adhesive properties of the integrin leucocyte function-associated antigen I (LFA-I). Biochemical Society Transactions, 1997, 25, 515-520.	1.6	16
400	A dendritic-cell-derived C–C chemokine that preferentially attracts naive T cells. Nature, 1997, 387, 713-717.	13.7	480
401	Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. , 1997, 70, 302-309.		76
402	Intracellular carotenoid levels measured by Raman microspectroscopy: Comparison of lymphocytes from lung cancer patients and healthy individuals. International Journal of Cancer, 1997, 74, 20-25.	2.3	50
403	Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. , 1997, 70, 302.		2
404	Intracellular carotenoid levels measured by Raman microspectroscopy: Comparison of lymphocytes from lung cancer patients and healthy individuals. , 1997, 74, 20.		5
405	Analysis of Dendritic Cells at the Genetic Level. Advances in Experimental Medicine and Biology, 1997, 417, 443-448.	0.8	7
406	Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. Journal of Immunology, 1997, 158, 560-5.	0.4	71
407	Competition between lymphocyte function-associated antigen 1 (CD11a/CD18) and Mac-1 (CD11b/CD18) for binding to intercellular adhesion molecule-1 (CD54). Journal of Leukocyte Biology, 1996, 59, 648-655.	1.5	33
408	Dendritic Cells in Immune Response Induction. Stem Cells, 1996, 14, 501-507.	1.4	38
409	pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL. British Journal of Cancer, 1996, 73, 1044-1048.	2.9	25
410	Antibodies That Selectively Inhibit Leukocyte Function-associated Antigen 1 Binding to Intercellular Adhesion Molecule-3 Recognize a Unique Epitope within the CD11a I Domain. Journal of Biological Chemistry, 1996, 271, 9962-9968.	1.6	33
411	Critical amino acids in the lymphocyte function-associated antigen-1 I domain mediate intercellular adhesion molecule 3 binding and immune function Journal of Experimental Medicine, 1996, 183, 1247-1252.	4.2	41
412	KIM127, an Antibody that Promotes Adhesion, Maps to a Region of CD18 that Includes Cysteine-Rich Repeats. Cell Adhesion and Communication, 1995, 3, 375-384.	1.7	49
413	Antibodies that activate β2 integrins can generate different ligand binding states. European Journal of Immunology, 1995, 25, 637-643.	1.6	61
414	Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. International Journal of Cancer, 1995, 62, 97-102.	2.3	115

#	Article	IF	CITATIONS
415	Occurrence and a possible mechanism of penetration of natural killer cells into k562 target cells during the cytotoxic interaction. Cytometry, 1995, 20, 273-280.	1.8	16
416	Ins and outs of LFA-1. Trends in Immunology, 1995, 16, 479-483.	7.5	245
417	Allograft rejection in cattle with bovine leukocyte adhesion deficiency. Veterinary Immunology and Immunopathology, 1995, 48, 55-63.	0.5	7
418	Regulation of Human Monocyte Functions by Interleukin-10. Molecular Biology Intelligence Unit, 1995, , 37-52.	0.2	10
419	Phenotypic and functional changes in peripheral blood monocytes during progression of human immunodeficiency virus infection. Effects of soluble immune complexes, cytokines, subcellular particulates from apoptotic cells, and HIV-1-encoded proteins on monocytes phagocytic function, oxidative burst, transendothelial migration, and cell surface phenotype Journal of Clinical	3.9	49
420	Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Research, 1995, 55, 5330-4.	0.4	121
421	Extracellular Ca2+ modulates leukocyte function-associated antigen-1 cell surface distribution on T lymphocytes and consequently affects cell adhesion. Journal of Cell Biology, 1994, 124, 1061-1070.	2.3	133
422	Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes Journal of Experimental Medicine, 1994, 179, 1005-1009.	4.2	553
423	Changes in actin organization during the cytotoxic process. Cytometry, 1994, 15, 320-326.	1.8	11
424	Distinct binding of T lymphocytes to ICAM-1, -2 or -3 upon activation of LFA-1. European Journal of Immunology, 1994, 24, 2155-2160.	1.6	86
425	Molecular characterization of the melanocyte lineage-specific antigen gp100. Journal of Biological Chemistry, 1994, 269, 20126-33.	1.6	124
426	Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells. International Journal of Cancer, 1993, 54, 315-321.	2.3	77
427	Role of LFA-1/ICAM-1 in interleukin-2-stimulated lymphocyte proliferation. European Journal of Immunology, 1993, 23, 3292-3299.	1.6	32
428	Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon 1±. Cancer Immunology, Immunotherapy, 1993, 36, 163-170.	2.0	15
429	Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer. Cancer Immunology, Immunotherapy, 1993, 36, 210-213.	2.0	12
430	Effects of interleukin 4 on monocyte functions: comparison to interleukin 13. Research in Immunology, 1993, 144, 629-633.	0.9	46
431	Lymphocyte adhesion mediated by integrins. Research in Immunology, 1993, 144, 709-722.	0.9	8
432	De-novo expression of CD44 and survival in gastric cancer. Lancet, The, 1993, 342, 1019-1022.	6.3	230

#	Article	IF	CITATIONS
433	Immunization with Interleukin-2 Transfected Melanoma Cells. A Phase l–II Study in Patients with Metastatic Melanoma. University Hospital Leiden. Human Gene Therapy, 1993, 4, 323-330.	1.4	53
434	Role of Intracellular Ca2+Levels in the Regulation of CD11a/CD18 Mediated Cell Adhesion. Cell Adhesion, 1993, 1, 21-32.	1.7	43
435	Lymphocyte function-associated antigen 1 dominates very late antigen 4 in binding of activated T cells to endothelium Journal of Experimental Medicine, 1993, 177, 185-190.	4.2	70
436	Activation and Inactivation of Adhesion Molecules. Current Topics in Microbiology and Immunology, 1993, 184, 235-248.	0.7	7
437	Activation of LFA-1: Role of Cations. , 1993, , 14-24.		1
438	Activation of Lfa-1: The L16 Epitope is a Cation-Binding Reporter. , 1993, , 181-194.		0
439	The MHC Expression of Dendritic Cells from Mouse Spleen Isolated by Centrifugal Elutriation is Upregulated During Short Term Culture. Advances in Experimental Medicine and Biology, 1993, 329, 185-189.	0.8	0
440	Regulatory effect of interleukin-4 (IL-4) on the expression and function of lymphocyte adhesion receptors involved in IL-2-induced cell aggregation. Immunology, 1993, 78, 244-51.	2.0	6
441	Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. American Journal of Pathology, 1993, 143, 1579-85.	1.9	73
442	Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. Journal of Immunology, 1993, 151, 767-76.	0.4	157
443	Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. Journal of Immunology, 1993, 151, 6370-81.	0.4	457
444	Adhesion of T and B lymphocytes to extracellular matrix and endothelial cells can be regulated through the beta subunit of VLA. Journal of Cell Biology, 1992, 117, 461-470.	2.3	129
445	Monocyte mediated cytotoxic activity against melanoma. Melanoma Research, 1992, 1, 303-310.	0.6	21
446	A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation. Journal of Immunological Methods, 1992, 155, 101-111.	0.6	9
447	Phorbol ester-induced promyelocytic leukemia cell adhesion to marrow stromal cells involves fibronectin specific ?5?1 integrin receptors. Journal of Cellular Physiology, 1992, 153, 95-102.	2.0	19
448	Both LFA-1-positive and -deficient T cell clones require the CD2/LFA-3 interaction for specific cytolytic activation. European Journal of Immunology, 1992, 22, 1467-1475.	1.6	18
449	Differential cytostatic activity of monocyte-derived cytokines against human melanoma cells. International Journal of Cancer, 1992, 50, 746-751.	2.3	5
450	Activation of LFA-1, and its role in mediating adhesion of monocytes and lymphocytes to endothelium. , 1992, , 117-122.		0

#	Article	IF	CITATIONS
451	Role of LFA-1 and VLA-4 in the adhesion of cloned normal and LFA-1 (CD11/CD18)-deficient T cells to cultured endothelial cells. Indication for a new adhesion pathway. Journal of Immunology, 1992, 148, 1093-101.	0.4	27
452	Regulation of aminopeptidase-N (CD13) and Fc epsilon RIIb (CD23) expression by IL-4 depends on the stage of maturation of monocytes/macrophages. Journal of Immunology, 1992, 149, 1395-401.	0.4	30
453	IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. Journal of Immunology, 1992, 149, 4048-52.	0.4	164
454	Induction of LFA-1-mediated homotypic adhesions in promonocytic U-937 cells occurs independently of cell differentiation. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1092, 165-168.	1.9	7
455	Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes Journal of Experimental Medicine, 1991, 174, 1209-1220.	4.2	3,556
456	Regulation of LFA-1-mediated T cell adhesion by CD4. European Journal of Immunology, 1991, 21, 887-894.	1.6	21
457	Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clinical and Experimental Metastasis, 1991, 9, 259-272.	1.7	108
458	Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression Journal of Experimental Medicine, 1991, 174, 915-924.	4.2	1,845
459	Activation of LFA-1 through a Ca2(+)-dependent epitope stimulates lymphocyte adhesion Journal of Cell Biology, 1991, 112, 345-354.	2.3	205
460	Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies. Cancer Immunology, Immunotherapy, 1990, 32, 245-250.	2.0	39
461	On the mode of action of LFA-1. Trends in Immunology, 1990, 11, 277-280.	7.5	204
462	The Role of LFA-1 and Related Antigens in Adhesion-Mediated Functions of Human Monocytes. , 1990, , 159-169.		2
463	Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood, 1990, 76, 1392-7.	0.6	117
464	IL-4 decreases Fc gamma R membrane expression and Fc gamma R-mediated cytotoxic activity of human monocytes. Journal of Immunology, 1990, 144, 3046-51.	0.4	90
465	IFN-alpha and IFN-gamma have different regulatory effects on IL-4-induced membrane expression of Fc epsilon RIIb and release of soluble Fc epsilon RIIb by human monocytes. Journal of Immunology, 1990, 144, 3052-9.	0.4	41
466	Expression of neural cell adhesion molecule-related sialoglycoprotein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Research, 1990, 50, 1102-6.	0.4	124
467	Triggering of the CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA-1 pathway. Journal of Immunology, 1990, 145, 3589-93.	0.4	142
468	Modulation of phenotypic and functional properties of human peripheral blood monocytes by interleukin-4 (IL-4). Agents and Actions, 1989, 26, 199-200.	0.7	3

#	Article	IF	CITATIONS
469	Characterization of a novel myeloid antigen regulated during differentiation of monocytic cells. European Journal of Immunology, 1989, 19, 1373-1378.	1.6	37
470	Ternary representation of trivariate data. Cytometry, 1989, 10, 77-80.	1.8	2
471	Enhancement of LFA-1-mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes. Nature, 1989, 342, 811-813.	13.7	450
472	Rapid densitometric determination of cell migration and cell adhesion in a microchemotaxis chamber. Journal of Immunological Methods, 1989, 118, 47-52.	0.6	9
473	Scattering matrix elements of biological particles measured in a flow through system: theory and practice. Applied Optics, 1989, 28, 1752.	2.1	30
474	Osmotic response of lymphocytes measured by means of forward light scattering: Theoretical considerations. Cytometry, 1988, 9, 636-641.	1.8	60
475	Computer-assisted centrifugal elutriation. II. Multiparametric statistical analysis. Computer Methods and Programs in Biomedicine, 1988, 27, 37-46.	2.6	6
476	A monoclonal antibody (NKI-L16) directed against a unique epitope on the alpha-chain of human leukocyte function-associated antigen 1 induces homotypic cell-cell interactions. Journal of Immunology, 1988, 140, 1393-400.	0.4	189
477	Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. Journal of Immunology, 1988, 140, 1548-54.	0.4	202
478	Spectral analysis of flow cytometric data: Design of a special-purpose low-pass digital filter. Cytometry, 1987, 8, 545-551.	1.8	4
479	Role of p150,95 in adhesion, migration, chemotaxis and phagocytosis of human monocytes. European Journal of Immunology, 1987, 17, 1317-1322.	1.6	153
480	Computer-assisted centrifugal elutriation. I. Detection system and data acquisition equipment. Computer Methods and Programs in Biomedicine, 1987, 24, 179-188.	2.6	7
481	Separation of Subpopulations from Heterogeneous Human Monocytes. , 1987, , 295-308.		1
482	Differential function of LFA-1 family molecules (CD11 and CD18) in adhesion of human monocytes to melanoma and endothelial cells. Immunology, 1987, 61, 261-7.	2.0	78
483	Membrane glycoprotein p150,95 of human cytotoxic T cell clone is involved in conjugate formation with target cells. Journal of Immunology, 1987, 138, 3130-6.	0.4	80
484	Elastic light scattering from nucleated blood cells: rapid numerical analysis. Applied Optics, 1986, 25, 3559.	2.1	29
485	Sensitive and quantitative determination of monocyte adherence. Journal of Immunological Methods, 1986, 95, 141-147.	0.6	7
486	Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. International Journal of Cancer, 1986, 38, 465-473.	2.3	90

#	Article	IF	CITATIONS
487	Concentration of Hematopoietic Progenitor Cells from Human Bone Marrow by a New Type of Blood Component Separator. Vox Sanguinis, 1985, 49, 154-160.	0.7	3
488	Biochemical and functional characteristics of the human leukocyte membrane antigen family LFA-1, Mo-1 and p!50,95. European Journal of Immunology, 1985, 15, 1142-1148.	1.6	161
489	A centrifugal elutriation system of separating small numbers of cells. Journal of Immunological Methods, 1984, 68, 73-87.	0.6	25
490	Purine Metabolism in Human Thymocyte Subsets: Relevance for Lymphocytic Differentiation. Advances in Experimental Medicine and Biology, 1984, 165 Pt B, 99-106.	0.8	1
491	Lymphocyte Maturation in the Human Thymus Scandinavian Journal of Immunology, 1983, 18, 539-549.	1.3	12
492	Theory and practice of centrifugal elutriation (CE). Cell Biophysics, 1983, 5, 105-118.	0.4	51
493	Rapid isolation of mononuclear cells from buffy coats prepared by a new blood cell separator. Journal of Immunological Methods, 1982, 55, 221-229.	0.6	10
494	The Replacement of Monocytes and Interleukin-1 by Phorbol Ester in Lectin-Induced Proliferation of Human Thymocytes and T Cells. Immunobiology, 1982, 162, 103-115.	0.8	25
495	REGULATION OF HUMAN NK ACTIVITY AGAINST ADHERENT TUMOR TARGET CELLS BY MONOCYTE SUBPOPULATIONS, INTERLEUKIN-1, AND INTERFERONS. , 1982, , 657-668.		7
496	Isolation of human thymocytes differing in maturation state and function by centrifugal elutriation. Thymus, 1982, 4, 243-56.	0.5	6
497	Isolation of functionally different human monocytes by counterflow centrifugation elutriation. Blood, 1982, 60, 46-53.	0.6	31
498	Isolation of large numbers of highly purified lymphocytes and monocytes with a modified centrifugal elutriation technique. Journal of Immunological Methods, 1981, 40, 275-288.	0.6	67
499	In vitro anti-tumour activity of tumour necrosis serum. International Journal of Immunopharmacology, 1980, 2, 95-100.	1.1	10
500	Triterpene Composition of Hoya australis Cuticular Wax in Relation to Leaf Age. Zeitschrift Für Pflanzenphysiologie, 1978, 87, 243-253.	1.4	15
501	Isolation of a New seco-nor-Triterpenol from Hoya australis Leaf Wax. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 1978, 33, 337-339.	0.6	6
502	C-Type Lectins: Multifaceted Receptors in Phagocyte Biology. , 0, , 123-135.		0